Ionis Pharmaceuticals (IONS) Cash from Investing Activities (2009 - 2026)

Ionis Pharmaceuticals' Cash from Investing Activities history runs 18 years deep, the most recent figure standing at $536.8 million for Q1 2026.

• In Q1 2026, Cash from Investing Activities rose 214.93% year-over-year to $536.8 million; the TTM figure through Mar 2026 stood at $88.6 million (up 323.29% YoY), while the FY2025 annual figure was -$277.8 million, down 107.25% from the prior year.
• Cash from Investing Activities was $536.8 million for Q1 2026 at Ionis Pharmaceuticals, up from -$419.5 million in the prior quarter.
• In the past five years, Cash from Investing Activities ranged from a high of $536.8 million in Q1 2026 to a low of -$419.5 million in Q4 2025.
• Historically, Cash from Investing Activities has averaged -$20.7 million across 5 years, with a median of $62.4 million in 2024.
• The sharpest annual moves came in 2023 and 2025: Cash from Investing Activities soared 2203.96% in 2023, then slumped 714.99% in 2025.
• A 5-year view of Cash from Investing Activities shows it stood at $212.1 million in 2022, then tumbled by 112.59% to -$26.7 million in 2023, then surged by 355.36% to $68.2 million in 2024, then plunged by 714.99% to -$419.5 million in 2025, then soared by 227.97% to $536.8 million in 2026.
• The last three Cash from Investing Activities figures came in at $536.8 million (Q1 2026), -$419.5 million (Q4 2025), and $91.3 million (Q3 2025), per Business Quant data.